BR112023016352A2 - Anticorpo anti-cd38 ou fragmento de anticorpo para uso - Google Patents

Anticorpo anti-cd38 ou fragmento de anticorpo para uso

Info

Publication number
BR112023016352A2
BR112023016352A2 BR112023016352A BR112023016352A BR112023016352A2 BR 112023016352 A2 BR112023016352 A2 BR 112023016352A2 BR 112023016352 A BR112023016352 A BR 112023016352A BR 112023016352 A BR112023016352 A BR 112023016352A BR 112023016352 A2 BR112023016352 A2 BR 112023016352A2
Authority
BR
Brazil
Prior art keywords
antibody
fragment
felzartamab
present
antibody fragment
Prior art date
Application number
BR112023016352A
Other languages
English (en)
Portuguese (pt)
Inventor
Rainer Boxhammer
Stefan Härtle
Stefan Steidl
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of BR112023016352A2 publication Critical patent/BR112023016352A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
BR112023016352A 2021-03-01 2022-03-01 Anticorpo anti-cd38 ou fragmento de anticorpo para uso BR112023016352A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21159860 2021-03-01
PCT/EP2022/055080 WO2022184676A1 (en) 2021-03-01 2022-03-01 Anti-cd38 antibodies for use in the treatment of antibody-mediated transplant rejection

Publications (1)

Publication Number Publication Date
BR112023016352A2 true BR112023016352A2 (pt) 2023-10-03

Family

ID=74844778

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023016352A BR112023016352A2 (pt) 2021-03-01 2022-03-01 Anticorpo anti-cd38 ou fragmento de anticorpo para uso

Country Status (12)

Country Link
US (1) US20240228654A9 (cg-RX-API-DMAC10.html)
EP (1) EP4301779A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024507986A (cg-RX-API-DMAC10.html)
KR (1) KR20230154239A (cg-RX-API-DMAC10.html)
AU (1) AU2022230717A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023016352A2 (cg-RX-API-DMAC10.html)
CA (1) CA3209172A1 (cg-RX-API-DMAC10.html)
CL (1) CL2023002495A1 (cg-RX-API-DMAC10.html)
IL (1) IL304692A (cg-RX-API-DMAC10.html)
MX (1) MX2023009868A (cg-RX-API-DMAC10.html)
TW (1) TW202302642A (cg-RX-API-DMAC10.html)
WO (1) WO2022184676A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202545561A (zh) * 2024-01-16 2025-12-01 德商莫菲西斯有限責任公司 抗體的高度濃縮液體製劑

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020164788A1 (en) 1994-12-02 2002-11-07 The Wellcome Foundation Limited Humanized antibodies to CD38
AU770718B2 (en) 1998-06-05 2004-02-26 Mayo Foundation For Medical Education And Research Use of genetically engineered antibodies to CD38 to treat multiple myeloma
US7223397B1 (en) 1999-01-07 2007-05-29 Research Development Foundation Potentiation of anti-CD38-Immunotoxin cytotoxicity
EP1174440A1 (en) 2000-07-19 2002-01-23 U-BISys B.V. A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment
EP2915820A1 (en) 2004-02-06 2015-09-09 MorphoSys AG Anti-CD38 human antibodies and uses therefor
EP2551282A3 (en) 2005-03-23 2013-02-13 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
TW200745162A (en) 2005-05-24 2007-12-16 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
CN101287764B (zh) 2005-10-12 2013-11-13 莫佛塞斯公司 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定
PL2081595T3 (pl) 2006-09-26 2019-11-29 Genmab As Anty-cd38 wraz z kortykosteroidami wraz ze środkiem chemioterapeutycznym niebędącym kortykosteroidem, do leczenia guzów nowotworowych
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EP2191842A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
EP2191841A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
EP2191840A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
EP2191843A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
PE20171094A1 (es) 2014-12-04 2017-08-07 Janssen Biotech Inc Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda
EP3313441B1 (en) 2015-06-24 2024-02-21 Janssen Biotech, Inc. Immune modulation and treatment of solid tumors with antibodies that specifically bind cd38
WO2018002181A1 (en) 2016-06-28 2018-01-04 Umc Utrecht Holding B.V. TREATMENT OF IgE-MEDIATED DISEASES WITH ANTIBODIES THAT SPECIFICALLY BIND CD38
EP3434692A1 (en) 2017-07-24 2019-01-30 Encefa Compounds which specifically binds to cd38 for use in the treatment of neurodegenerative diseases
WO2020185672A1 (en) 2019-03-08 2020-09-17 Cedars-Sinai Medical Center Anti-cd38 agents for desensitization and treatment of antibody-mediated rejection of organ transplants
TWI924633B (zh) 2019-03-15 2026-05-11 德商莫菲西斯公司 用於治療自體抗體介導的自體免疫疾病的抗-cd38 抗體及其醫藥組成物

Also Published As

Publication number Publication date
WO2022184676A1 (en) 2022-09-09
TW202302642A (zh) 2023-01-16
KR20230154239A (ko) 2023-11-07
IL304692A (en) 2023-09-01
CA3209172A1 (en) 2022-09-09
EP4301779A1 (en) 2024-01-10
US20240228654A9 (en) 2024-07-11
CL2023002495A1 (es) 2023-12-29
US20240132618A1 (en) 2024-04-25
AU2022230717A1 (en) 2023-09-14
JP2024507986A (ja) 2024-02-21
MX2023009868A (es) 2023-08-29

Similar Documents

Publication Publication Date Title
CL2024002250A1 (es) Uso de anticuerpo anti-vd1 para tratar cáncer, una enfermedad infecciosa o una enfermedad inflamatoria.
CL2021002389A1 (es) Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y uso del agente para tratar o prevenir trastornos cognitivos. (divisional de la solicitud 201902296)
EA201890578A1 (ru) Предотвращение, лечение и снижение (персистирующей) посттравматической головной боли
BR112023024906A2 (pt) Compostos
EA202092825A1 (ru) Анти-sirpa антитела и способы их применения
BR112022019892A2 (pt) Métodos para tratar e/ou retardar a progressão de uma doença ou lesão e para monitorar o tratamento de um indivíduo
WO2021212021A3 (en) Coronavirus antibodies and methods of use thereof
BR112023004830A2 (pt) Métodos para tratamento de mieloma múltiplo
EA202190138A1 (ru) Анти-sirp-бета1 антитела и способы их использования
WO2022051591A3 (en) Nectin-4 antibodies and uses thereof
BRPI0211953B8 (pt) anticorpo monoclonal ou fragmento de ligação a antígeno que se liga a c5 e c5a sem a prevenção da formação de c5b, linhagem celular, composição farmacêutica, bem como método in vitro para inibir a atividade de c5a e método de diagnóstico in vitro
CL2022000230A1 (es) Anticuerpos anti-ms4a4a y métodos de uso de los mismos
AR079458A2 (es) Anticuerpo monoclonal quimerico que se une a cd45
PH12019501425A1 (en) Human antibodies to s. aureus hemolysin a toxin
BR112021008060A2 (pt) Polipeptídeo, anticorpo anti-ctla4 ou fragmento de anticorpo, imunoconjugado, composição farmacêutica, dose única de composição farmacêutica, método de tratar câncer, e, kit para diagnóstico ou tratamento
CL2023003696A1 (es) Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, métodos de uso
BR112021014699A2 (pt) Métodos de tratamento de mieloma múltiplo
BRPI0907135B8 (pt) uso de um anticorpo antagonista anti-cgrp para a prevenção e/ou tratamento de dor de câncer crônica
CO2020013833A2 (es) Anticuerpo anti-muerte programada-ligando 1 y su uso
MX2025007409A (es) Anticuerpos inhibidores selectivos y potentes de la activacion de miostatina
BR112016006428A2 (pt) anticorpo, fragmento de ligação a antígeno do anticorpo, composição farmacêutica, métodos para tratamento e/ou profilaxia de infecção por pseudomona e para produzir um anticorpo, agente de diagnóstico para infecção por pseudomona, kit de detecção para pseudomonas aeruginosa, polinucleotídeo, vetor, e, célula hospedeira transformada
MX2021011181A (es) Anticuerpos anti-cd38 y sus composiciones farmacéuticas para el tratamiento de la enfermedad autoinmune mediada por autoanticuerpos.
EA202190183A1 (ru) Антитела к siglec-5 и способы их применения
MX2020008122A (es) Anticuerpos anti-pd-1.
BR112022002142A2 (pt) Anticorpos anti-bdca-2